INSM vs. TEVA: Insmed vs. Teva Pharmaceutical Stock Comparison

Company Profile

Insmed (INSM) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Insmed (INSM) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Teva Pharmaceutical (TEVA) reports 6.65%, ranking against industry peers normally.

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Teva Pharmaceutical (TEVA) reports 2.94%, ranking against industry peers normally.

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Teva Pharmaceutical (TEVA) reports 27.40%, ranking against industry peers normally.

Profitability Metrics

Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Teva Pharmaceutical (TEVA) at 4.31% is closer to the peer norm — faster top-line expansion for INSM.

Neither Insmed (INSM) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Insmed (INSM) at 1.01 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither Insmed (INSM) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Insmed (INSM) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Insmed (INSM) at 16.52 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Teva Pharmaceutical (TEVA) at 6.23 sits near its industry’s typical P/B ratio, while Insmed (INSM) at 34.55 prices above its benchmark range — INSM looks rich relative to book.

Valuation Metrics